Using skin for drug delivery and diagnosis in the critically ill

Advanced Drug Delivery Reviews

Volumn 77, Issue , 2014, Pages 40-49

  Liu, Xin ^a   Kruger, Peter ^a,b   Maibach, Howard ^c   Colditz, Paul B ^a,e   Roberts, Michael S ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Critically ill; Diagnosis; Drug delivery; Intensive care; Skin

Indexed keywords

ANESTHETICS; DIAGNOSIS; DRUG DELIVERY; SKIN; TARGETED DRUG DELIVERY;

CRITICALLY ILLS; CRITICALLY-ILL PATIENTS; DIAGNOSTIC TOOLS; INTENSIVE CARE; LOCAL ANAESTHETIC; MULTI SYSTEMS; PATIENT POPULATION; SKIN PHYSIOLOGY;

CONTROLLED DRUG DELIVERY;

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; FENTANYL; HEPARIN; OPIATE;

ANTIMICROBIAL THERAPY; BODY FLUID; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; HUMAN; REVIEW; SKIN; SKIN BLOOD FLOW; SKIN FUNCTION; SKIN INJURY; SKIN STRUCTURE; SKIN TEMPERATURE; TOPICAL ANESTHESIA; TRANSDERMAL DRUG DELIVERY SYSTEM; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; METABOLISM; PATHOPHYSIOLOGY; SKIN ABSORPTION; SKIN DISEASES;

CRITICAL ILLNESS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG DELIVERY SYSTEMS; HUMANS; SKIN; SKIN ABSORPTION; SKIN DISEASES;

EID: 84919443314     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.004     Document Type: Review

References (144)

1. Power B.M., Forbes A.M., van Heerden P.V., Ilett K.F. Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet. 1998, 34:25-56.
2. Kane-Gill S.L., Kirisci L., Verrico M.M., Rothschild J.M. Analysis of risk factors for adverse drug events in critically ill patients. Crit. Care Med. 2012, 40:823-828.
3. Roberts M.S., Walters K.A. Human skin morphology and dermal absorption. Dermal absorption and toxicity assessment 2008, 1-15. Healthcare, New York. M.S. Roberts, K.A. Walters (Eds.).
4. Menon G.K. New insights into skin structure: scratching the surface. Adv. Drug Deliv. Rev. 2002, 54:S3-S17.
5. Sawynok J. Topical and peripherally acting analgesics. Pharmacol. Rev. 2003, 55:1-20.
6. Kaur I.P., Kakkar S. Topical delivery of antifungal agents. Expert Opin. Drug Deliv. 2010, 7:1303-1327.
7. Roberts M.S., Cross S.E., Pellett M.A. Skin transport. Dermatological and transdermal formulations 2002, 94-99. Marcel Dekker, New York. K.A. Walters (Ed.).
8. Elias P.M., Friend D.S. The permeability barrier in mammalian epidermis. J. Cell Biol. 1975, 65:180-191.
9. Downing D.T. Lipid and protein structures in the permeability barrier of mammalian epidermis. J. Lipid Res. 1992, 33:301-313.
10. Perumal O., Murthy S.N., Kalia Y.N. Turning theory into practice: the development of modern transdermal drug delivery systems and future trends. Skin Pharmacol. Physiol. 2013, 26:331-342.
11. Afshari A., Brok J., Moller A.M., Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth. Analg. 2011, 112:1411-1421.
12. McLennan D.N., Porter C.J.H., Charman S.A. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov. Today: Technol. 2005, 2:89-96.
13. Dychter S.S., Gold D.A., Haller M.F. Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J. Infus. Nurs. 2012, 35:154-160.
14. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 1990, 7:167-169.
15. Zuidema J., Kadir F., Titulaer H.A.C., Oussoren C. Release and Absorption Rates of Intramuscularly and Subcutaneously Injected Pharmaceuticals (II). Int. J. Pharm. 1994, 105:189-207.
16. Silbergleit R., Lowenstein D., Durkalski V., Conwit R. Lessons from the RAMPART study-and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia 2013, 54(Suppl. 6):74-77.
17. Henning R.J., Wiener F., Valdes S., Weil M.H. Measurement of toe temperature for assessing the severity of acute circulatory failure. Surg. Gynecol. Obstet. 1979, 149:1-7.
18. Astiz M.E., Rackow E.C. Assessing perfusion failure during circulatory shock. Crit. Care Clin. 1993, 9:299-312.
19. Sommers M.S., Stevenson J.S., Hamlin R.L., Ivey T.D. Skin temperature and limb blood flow as predictors of cardiac index. Clin. Nurs. Res. 1995, 4:22-37.
20. Carrillo A.E., Cheung S.S., Flouris A.D. A novel model to predict cutaneous finger blood flow via finger and rectal temperatures. Microcirculation 2011, 18:670-676.
21. Curley F., Smyrnios N. Routine monitoring of critically ill patients. Intensive care med 2003, 250-270. Williams & Wilkins, New York. R. Irwin, F. Cerra, J. Rippe (Eds.).
22. Lima A., Bakker J. Noninvasive monitoring of peripheral perfusion. Intensive Care Med. 2005, 31:1316-1326.
23. Ibsen B. Treatment of shock with vasodilators measuring skin temperature on the big toe. Ten years' experience in 150 cases. Dis. Chest 1967, 52:425-429.
24. Joly H.R., Weil M.H. Temperature of the great toe as an indication of the severity of shock. Circulation 1969, 39:131-138.
25. Brozek J., Keys A. The evaluation of leanness-fatness in man; norms and interrelationships. Br. J. Nutr. 1951, 5:194-206.
26. Addo O.Y., Pereira M.A., Himes J.H. Is skinfold thickness as good as DXA when measuring adiposity contributions to insulin resistance in adolescents?. Am. J. Hum. Biol. 2012, 24:806-811.
27. Zoccali C., Torino C., Tripepiand G., Mallamaci F. Assessment of obesity in chronic kidney disease: what is the best measure?. Curr. Opin. Nephrol. Hypertens. 2012, 21:641-646.
28. Jaworski M., Kulaga Z., Pludowski P., Grajda A., Gurzkowska B., Napieralska E., Swiader A., Pan H.Q., Litwin M., Grp O.S. Population-based centile curves for triceps, subscapular, and abdominal skinfold thicknesses in Polish children and adolescents-the OLAF study. Eur. J. Pediatr. 2012, 171:1215-1221.
29. Durnin J.V., Rahaman M.M. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br. J. Nutr. 1967, 21:681-689.
30. Buchholz A.C., Bartok C., Schoeller D.A. The validity of bioelectrical impedance models in clinical populations. Nutr. Clin. Pract. 2004, 19:433-446.
31. Heymsfield S.B., Wang Z.M., Visser M., Gallagher D., Pierson R.N. Techniques used in the measurement of body composition: An overview with emphasis on bioelectrical impedance analysis. Am. J. Clin. Nutr. 1996, 64:S478-S484.
32. Ishibe S., Peixoto A.J. Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice. Semin. Dial. 2004, 17:37-43.
33. Kyle U.G., Bosaeus I., De Lorenzo A.D., Deurenberg P., Elia M., Gomez J.M., Heitmann B.L., Kent-Smith L., Melchior J.C., Pirlich M., Scharfetter H., Schols A.M., Pichard C., Composition of the ESPEN Working Group Bioelectrical impedance analysis - part I: review of principles and methods. Clin. Nutr. 2004, 23:1226-1243.
34. Steingrub J.S. Bioelectrical impedance monitoring: is this a bull market for electric utilities?. Crit. Care Med. 2000, 28:273-275.
35. Allen K.J. Food allergy: is there a rising prevalence and if so why?. Med. J. Aust. 2011, 195:5-7.
36. Li J.T. Allergy testing. Am. Fam. Physician 2002, 66:621-624.
37. Mattar A.C., Leone C., Rodrigues J.C., Adde F.V. Sweat conductivity: An accurate diagnostic test for cystic fibrosis?. J. Cyst. Fibros. 2014, 13:528-533.
38. Wing D., Prausnitz M.R., Buono M.J. Skin pretreatment with microneedles prior to pilocarpine iontophoresis increases sweat production. Clin. Physiol. Funct. Imaging 2013, 33:436-440.
39. Konig K., Raphael A.P., Lin L., Grice J.E., Soyer H.P., Breunig H.G., Roberts M.S., Prow T.W. Applications of multiphoton tomographs and femtosecond laser nanoprocessing microscopes in drug delivery research. Adv. Drug Deliv. Rev. 2011, 63:388-404.
40. Prow T.W., Grice J.E., Lin L.L., Faye R., Butler M., Becker W., Wurm E.M., Yoong C., Robertson T.A., Soyer H.P., Roberts M.S. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 2011, 63:470-491.
41. Glickman Y.A., Filo O., David M., Yayon A., Topaz M., Zamir B., Ginzburg A., Rozenman D., Kenan G. Electrical impedance scanning: a new approach to skin cancer diagnosis. Skin Res. Technol. 2003, 9:262-268.
42. Schaefer M.S., Wania V., Bastin B., Schmalz U., Kienbaum P., Beiderlinden M., Treschan T.A. Electrical impedance tomography during major open upper abdominal surgery: a pilot-study. BMC Anesthesiol. 2014, 14:51.
43. Mahle W.T., Newburger J.W., Matherne G.P., Smith F.C., Hoke T.R., Koppel R., Gidding S.S., Beekman R.H., Grosse S.D. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation 2009, 120:447-458.
44. East C.E., Colditz P.B. Intrapartum oximetry of the fetus. Anesth. Analg. 2007, 105:S59-S65.
45. Joukhadar C., Klein N., Mayer B.X., Kreischitz N., Delle-Karth G., Palkovits P., Heinz G., Muller M. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit. Care Med. 2002, 30:1478-1482.
46. Azeredo F.J., Dalla Costa T., Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin. Pharmacokinet. 2014, 53:205-212.
47. Kitagawa R., Yokobori S., Mazzeo A.T., Bullock R. Microdialysis in the neurocritical care unit. Neurosurg. Clin. N. Am. 2013, 24:417-426.
48. Roberts J.A., Roberts M.S., Semark A., Udy A.A., Kirkpatrick C.M.J., Paterson D.L., Roberts M.J., Kruger P., Lipman J. Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011, 11:3.
49. Vincent J.L., De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit. Care 2005, 9:S9-S12.
50. Shupp J.W., Nasabzadeh T.J., Rosenthal D.S., Jordan M.H., Fidler P., Jeng J.C. A review of the local pathophysiologic bases of burn wound progression. J. Burn Care Res. 2010, 31:849-873.
51. Neely A.N., Gardner J., Durkee P., Warden G.D., Greenhalgh D.G., Gallagher J.J., Herndon D.N., Tompkins R.G., Kagan R.J. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics?. J. Burn Care Res. 2009, 30:19-29.
52. Taddonio T.E., Thomson P.D., Smith D.J., Prasad J.K. A survey of wound monitoring and topical antimicrobial therapy practices in the treatment of burn injury. J. Burn Care Rehabil. 1990, 11:423-427.
53. Fox C.L. Silver sulfadiazine - a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch. Surg. 1968, 96:184-188.
54. Morsi N.M., Abdelbary G.A., Ahmed M.A. Silver sulfadiazine based cubosome hydrogels for topical treatment of burns: Development and in vitro/in vivo characterization. Eur. J. Pharm. Biopharm. 2014, 86:178-189.
55. Heo D.N., Yang D.H., Lee J.B., Bae M.S., Kim J.H., Moon S.H., Chun H.J., Kim C.H., Lim H.N., Kwon I.K. Burn-wound healing effect of gelatin/polyurethane nanofiber scaffold containing silver-sulfadiazine. J. Biomed. Nanotechnol. 2013, 9:511-515.
56. Morones J.R., Elechiguerra J.L., Camacho A., Holt K., Kouri J.B., Ramirez J.T., Yacaman M.J. The bactericidal effect of silver nanoparticles. Nanotechnology 2005, 16:2346-2353.
57. Gravante G., Caruso R., Sorge R., Nicoli F., Gentile P., Cervelli V. Nanocrystalline silver: a systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Ann. Plast. Surg. 2009, 63:201-205.
58. Varas R.P., O'Keeffe T., Namias N., Pizano L.R., Quintana O.D., Herrero Tellachea M., Rashid Q., Ward C.G. A prospective, randomized trial of Acticoat versus silver sulfadiazine in the treatment of partial-thickness burns: which method is less painful?. J. Burn Care Rehabil. 2005, 26:344-347.
59. Peters D.A., Verchere C. Healing at home: Comparing cohorts of children with medium-sized burns treated as outpatients with in-hospital applied Acticoat (TM) to those children treated as inpatients with silver sulfadiazine. J. Burn Care Res. 2006, 27:198-201.
60. Tian J., Wong K.K., Ho C.M., Lok C.N., Yu W.Y., Che C.M., Chiu J.F., Tam P.K. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007, 2:129-136.
61. Lipsky B.A., Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin. Infect. Dis. 2009, 49:1541-1549.
62. Lyder C.H. Pressure ulcer prevention and management. JAMA 2003, 289:223-226.
63. Farsaei S., Khalili H., Farboud E.S. Potential role of statins on wound healing: review of the literature. Int. Wound J. 2012, 9:238-247.
64. Toker S., Gulcan E., Cayc M.K., Olgun E.G., Erbilen E., Ozay Y. Topical atorvastatin in the treatment of diabetic wounds. Am. J. Med. Sci. 2009, 338:201-204.
65. Rego A.C., Araujo Filho I., Damasceno B.P., Egito E.S., Silveira I.A., Brandao-Neto J., Medeiros A.C. Simvastatin improves the healing of infected skin wounds of rats. Acta Cir. Bras. 2007, 22(Suppl. 1):57-63.
66. Farsaei S., Khalili H., Farboud E.S., Karimzadeh I., Beigmohammadi M.T. Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial. Pharmacotherapy 2014, 34:19-27.
67. Popovich K.J., Lyles R., Hayes R., Hota B., Trick W., Weinstein R.A., Hayden M.K. Relationship between chlorhexidine gluconate skin concentration and microbial density on the skin of critically ill patients bathed daily with chlorhexidine gluconate. Infect. Control Hosp. Epidemiol. 2012, 33:889-896.
68. Milstone A.M., Elward A., Song X., Zerr D.M., Orscheln R., Speck K., Obeng D., Reich N.G., Coffin S.E., Perl T.M., Pediatric S.T.S.G. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 2013, 381:1099-1106.
69. Climo M.W., Yokoe D.S., Warren D.K., Perl T.M., Bolon M., Herwaldt L.A., Weinstein R.A., Sepkowitz K.A., Jernigan J.A., Sanogo K., Wong E.S. Effect of daily chlorhexidine bathing on hospital-acquired infection. N. Engl. J. Med. 2013, 368:533-542.
70. Spencer C., Orr D., Hallam S., Tillmanns E. Daily bathing with octenidine on an intensive care unit is associated with a lower carriage rate of meticillin-resistant Staphylococcus aureus. J. Hosp. Infect. 2013, 83:156-159.
71. Oostdijk E.A.N., Smits L., de Smet A.M.G.A., Leverstein-van Hall M.A., Kesecioglu J., Bonten M.J.M. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med. 2013, 39:653-660.
72. Roberge R.J., Kelly M., Evans T.C., Hobbs E., Sayre M., Cottington E. Facilitated intravenous access through local application of nitroglycerin ointment. Ann. Emerg. Med. 1987, 16:546-549.
73. Hecker J.F., Lewis G.B.H., Stanley H. Nitroglycerine ointment as an aid to venipuncture. Lancet 1983, 1:332-333.
74. Lohmann M., Moller P., Brynitz S., Bjerrum O.W. Nitroglycerin ointment as aid to venepuncture. Lancet 1984, 1:1416-1417.
75. Mosalli R., Elbaz M., Paes B. Topical nitroglycerine for neonatal arterial associated peripheral ischemia following cannulation: A case report and comprehensive literature review. Case Rep. Pediatr. 2013, 2013:608516.
76. Roberge R.J. Venodilatation techniques to enhance venepuncture and intravenous cannulation. J. Emerg. Med. 2004, 27:69-73.
77. Doyle E., Freeman J., Im N.T., Morton N.S. An evaluation of a new self-adhesive patch preparation of amethocaine for topical anaesthesia prior to venous cannulation in children. Anaesthesia 1993, 48:1050-1052.
78. Tadicherla S., Berman B. Percutaneous dermal drug delivery for local pain control. Ther. Clin. Risk Manag. 2006, 2:99-113.
79. Ruetzler K., Sima B., Mayer L., Golescu A., Dunkler D., Jaeger W., Hoeferl M., You J., Sessler D.I., Grubhofer G., Hutschala D. Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. Br. J. Anaesth. 2012, 109:790-796.
80. Schulz-Stubner S. The critically ill patient and regional anesthesia. Curr. Opin. Anaesthesiol. 2006, 19:538-544.
81. Ahmedzai S., Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J. Pain Symptom Manage. 1997, 13:254-261.
82. Hans G., Robert D. Transdermal buprenorphine - a critical appraisal of its role in pain management. J Pain Res 2009, 2:117-134.
83. van Lersberghe C., Camu F., de Keersmaecker E., Sacre S. Continuous administration of fentanyl for postoperative pain: a comparison of the epidural, intravenous, and transdermal routes. J. Clin. Anesth. 1994, 6:308-314.
84. Miguel R., Kreitzer J.M., Reinhart D., Sebel P.S., Bowie J., Freedman G., Eisenkraft J.B. Postoperative pain control with a new transdermal fentanyl delivery system. A multicenter trial. Anesthesiology 1995, 83:470-477.
85. van Bastelaere M., Rolly G., Abdullah N.M. Postoperative analgesia and plasma levels after transdermal fentanyl for orthopedic surgery: double-blind comparison with placebo. J. Clin. Anesth. 1995, 7:26-30.
86. Freynhagen R., von Giesen H.J., Busche P., Sabatowski R., Konrad C., Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain. J. Pain Symptom Manage. 2005, 30:289-297.
87. Shomaker T.S., Zhang J., Ashburn M.A. Assessing the impact of heat on the systemic delivery of fentanyl through the transdermal fentanyl delivery system. Pain Med. 2000, 1:225-230.
88. Ashburn M.A., Ogden L.L., Zhang J., Love G., Basta S.V. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J. Pain 2003, 4:291-297.
89. Sekkat N., Kalia Y.N., Guy R.H. Porcine ear skin as a model for the assessment of transdermal drug delivery to premature neonates. Pharm. Res. 2004, 21:1390-1397.
90. Evans N.J., Rutter N., Hadgraft J., Parr G. Percutaneous administration of theophylline in the preterm infant. J. Pediatr. 1985, 107:307-311.
91. Djabri A., Guy R.H., Delgado-Charro M.B. Passive and iontophoretic transdermal delivery of phenobarbital: Implications in paediatric therapy. Int. J. Pharm. 2012, 435:76-82.
92. Boots I., Sukhai R.N., Klein R.H., Holl R.A., Wit J.M., Cohen A.F., Burggraaf J. Stimulation programs for pediatric drug research-do children really benefit?. Eur. J. Pediatr. 2007, 166:849-855.
93. Pansieri C., Bonati M., Choonara I., Jacqz-Aigrain E. Neonatal drug trials: impact of EU and US paediatric regulations. Arch. Dis. Child. Fetal Neonatal Ed. 2014, 99:F438.
94. Hudson T.L., Dukes S.F., Reilly K. Use of local anesthesia for arterial punctures. Am. J. Crit. Care 2006, 15:595-599.
95. Tobias J.D. Subcutaneous administration of fentanyl and midazolam to prevent withdrawal after prolonged sedation in children. Crit. Care Med. 1999, 27:2262-2265.
96. Dorffler-Melly J., de Jonge E., Pont A.C., Meijers J., Vroom M.B., Buller H.R., Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002, 359:849-850.
97. Priglinger U., Delle Karth G., Geppert A., Joukhadar C., Graf S., Berger R., Hulsmann M., Spitzauer S., Pabinger I., Heinz G. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?. Crit. Care Med. 2003, 31:1405-1409.
98. Krishnamurthy R.B., Upton R.N., Fajumi A.O., Lai S., Charlton C.S., Ousley R.M., Martinez A.M., McConnell H., O'Connor S.N., Ong J., Macintyre P.E., Chapman M.J., Ludbrook G.L. Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. Anaesth. Intensive Care 2012, 40:269-274.
99. Rommers M.K., Van der Lely N., Egberts T.C., van den Bemt P.M. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit. Care 2006, 10:R93.
100. Crowther M., Lim W. Measuring the anticoagulant effect of low molecular weight heparins in the critically ill. Crit. Care 2006, 10:150.
101. Sawh S.B., Selvaraj I.P., Danga A., Cotton A.L., Moss J., Patel P.B. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin. Proc. 2012, 87:255-259.
102. Vincent J.L. Give your patient a fast hug (at least) once a day. Crit. Care Med. 2005, 33:1225-1229.
103. Capes S.E., Hunt D., Malmberg K., Gerstein H.C. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000, 355:773-778.
104. Bochicchio G.V., Joshi M., Bochicchio K.M., Pyle A., Johnson S.B., Meyer W., Lumpkins K., Scalea T.M. Early hyperglycemic control is important in critically injured trauma patients. J. Trauma 2007, 63:1353-1358.
105. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., Sevransky J.E., Sprung C.L., Douglas I.S., Jaeschke R., Osborn T.M., Nunnally M.E., Townsend S.R., Reinhart K., Kleinpell R.M., Angus D.C., Deutschman C.S., Machado F.R., Rubenfeld G.D., Webb S.A., Beale R.J., Vincent J.L., Moreno R., S.Surviving Sepsis Campaign Guidelines Committee including the Pediatric Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2013, 41:580-637.
106. Investigators N.-S.S., Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., Dhingra V., Bellomo R., Cook D., Dodek P., Henderson W.R., Hebert P.C., Heritier S., Heyland D.K., McArthur C., McDonald E., Mitchell I., Myburgh J.A., Norton R., Potter J., Robinson B.G., Ronco J.J. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 2009, 360:1283-1297.
107. Dickerson R.N., Swiggart C.E., Morgan L.M., Maish G., Croce M.A., Minard G., Brown R.O. Safety and efficacy of a graduated intravenous insulin infusion protocol in critically ill trauma patients receiving specialized nutritional support. Nutrition 2008, 24:536-545.
108. Dickerson R.N., Wilson V.C., Maish G.O., Croce M.A., Minard G., Brown R.O. Transitional NPH insulin therapy for critically ill patients receiving continuous enteral nutrition and intravenous regular human insulin. JPEN J. Parenter. Enteral Nutr. 2013, 37:506-516.
109. Leelarathna L., English S.W., Thabit H., Caldwell K., Allen J.M., Kumareswaran K., Wilinska M.E., Nodale M., Mangat J., Evans M.L., Burnstein R., Hovorka R. Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Crit. Care 2013, 17:R159.
110. Harris D.L., Weston P.J., Signal M., Chase J.G., Harding J.E. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet 2013, 382:2077-2083.
111. Combadiere B., Liard C. Transcutaneous and intradermal vaccination. Hum. Vaccin. 2011, 7:811-827.
112. Fernando G.J., Chen X., Prow T.W., Crichton M.L., Fairmaid E.J., Roberts M.S., Frazer I.H., Brown L.E., Kendall M.A. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS ONE 2010, 5:e10266.
113. Leroux-Roels I., Weber F. Intanza (R) 9 microg intradermal seasonal influenza vaccine for adults 18 to 59years of age. Hum. Vaccin. Immunother. 2013, 9:115-121.
114. Guy B. Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective. J. Comp. Pathol. 2010, 142(Suppl. 1):S133-S137.
115. Schey B.M., Williams D.Y., Bucknall T. Skin temperature and core-peripheral temperature gradient as markers of hemodynamic status in critically ill patients: a review. Heart Lung 2010, 39:27-40.
116. Heymsfield S.B., Baumgartner R.N., Pan S.F. Nutritional assessment of malnutrition by anthropometric methods. Modern nutrition in health and disesae 1998, 903-921. Williams and Wilkins, Baltimore. M.E. Shils, J.A. Olson, M. Shike, A.C. Ross (Eds.).
117. Jacobs D.O. Use of bioelectrical impedance analysis measurements in the clinical management of critical illness. Am. J. Clin. Nutr. 1996, 64:S498-S502.
118. Plank L.D., Monk D.N., Woollard G.A., Hill G.L. Evaluation of multifrequency bioimpedance spectroscopy for measurement of the extracellular water space in critically ill patients. Appl. Radiat. Isot. 1998, 49:481-483.
119. Barbosa-Silva M.C.G., Barros A.J.D. Bioelectrical impedance analysis in clinical practice: a new perspective on its use beyond body composition equations. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:311-317.
120. Nescolarde L., Piccoli A., Roman A., Nunez A., Morales R., Tamayo J., Donate T., Rosell J. Bioelectrical impedance vector analysis in haemodialysis patients: relation between oedema and mortality. Physiol. Meas. 2004, 25:1271-1280.
121. Azevedo Z.M.A., Moore D.C.B.C., de Matos F.A.A., Fonseca V.M., Peixoto M.V.M., Gaspar-Elsas M.I.C., Santinoni E., dos Anjos L.A., Ramos E.G. Bioelectrical impedance parameters in critically ill children: Importance of reactance and resistance. Clin. Nutr. 2013, 32:824-829.
122. Hummler H.D., Engelmann A., Pohlandt F., Hogel J., Franz A.R. Decreased accuracy of pulse oximetry measurements during low perfusion caused by sepsis: Is the perfusion index of any value?. Intensive Care Med. 2006, 32:1428-1431.
123. Levrat Q., Petitpas F., Bouche G., Debaene B., Mimoz O. Usefulness of pulse oximetry using the SET technology in critically ill adult patients. Ann. Fr. Anesth. Reanim. 2009, 28:640-644.
124. Workie F.A., Rais-Bahrami K., Short B.L. Clinical use of new-generation pulse oximeters in the neonatal intensive care unit. Am. J. Perinatol. 2005, 22:357-360.
125. Inal M.T., Memis D., Kargi M., Sut N. Prognostic value of indocyanine green elimination assessed with LiMON in septic patients. J. Crit. Care 2009, 24:329-334.
126. Carino N.D., O'Reilly D.A., Dajani K., Ghaneh P., Poston G.J., Wu A.V. Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure. EJSO 2009, 35:957-962.
127. Stauber R.E., Wagner D., Stadlbauer V., Palma S., Gurakuqi G., Kniepeiss D., Iberer F., Smolle K.H., Haas J., Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int. 2009, 29:1516-1520.
128. Sakka S.G., Reinhart K., Meier-Hellmann A. Comparison of invasive and noninvasive measurements of indocyanine green plasma disappearance rate in critically ill patients with mechanical ventilation and stable hemodynamics. Intensive Care Med. 2000, 26:1553-1556.
129. Purcell R., Kruger P., Jones M. Indocyanine green elimination: a comparison of the LiMON and serial blood sampling methods. ANZ J. Surg. 2006, 76:75-77.
130. Mader J.K., Feichtner F., Bock G., Kohler G., Schaller R., Plank J., Pieber T.R., Ellmerer M. Microdialysis-a versatile technology to perform metabolic monitoring in diabetes and critically ill patients. Diabetes Res. Clin. Pract. 2012, 97:112-118.
131. Ramsay M. Role of microdialysis catheters in clinical decision making: bench to bedside?. Liver Transpl. 2013, 19:243-245.
132. Schwameis R., Zeitlinger M. Methods to measure target site penetration of antibiotics in critically ill patients. Curr. Clin. Pharmacol. 2013, 8:46-58.
133. Liu X., Kruger P.S., Roberts M.S. How to measure pharmacokinetics in critically ill patients?. Curr. Pharm. Biotechnol. 2011, 12:2037-2043.
134. Roberts J.A., Kirkpatrick C.M.J., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 2009, 64:142-150.
135. Cohen J., Deans R., Dalley A., Lipman J., Roberts M.S., Venkatesh B. Measurement of tissue cortisol levels in patients with severe burns: a preliminary investigation. Crit. Care 2009, 13:R189.
136. Mesotten D. Continuous glucose sensors for glycaemic control in the ICU: have we arrived?. Crit. Care 2013, 17:1004.
137. Buerger C., Plock N., Dehghanyar P., Joukhadar C., Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother. 2006, 50:2455-2463.
138. Zeitlinger M.A., Dehghanyar P., Mayer B.X., Schenk B.S., Neckel U., Heinz G., Georgopoulos A., Muller M., Joukhadar C. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob. Agents Chemother. 2003, 47:3548-3553.
139. Sanchez J.J., Bidot C.J., O'Phelan K., Gajavelli S., Yokobori S., Olvey S., Jagid J., Garcia J.A., Nemeth Z., Bullock R. Neuromonitoring with microdialysis in severe traumatic brain injury patients. Acta Neurochir. Suppl. 2013, 118:223-227.
140. Haugaa H., Thorgersen E.B., Pharo A., Boberg K.M., Foss A., Line P.D., Sanengen T., Almaas R., Grindheim G., Pischke S.E., Mollnes T.E., Tonnessen T.I. Early bedside detection of ischemia and rejection in liver transplants by microdialysis. Liver Transpl. 2012, 18:839-849.
141. Haugaa H., Almaas R., Thorgersen E.B., Foss A., Line P.D., Sanengen T., Bergmann G.B., Ohlin P., Waelgaard L., Grindheim G., Pischke S.E., Mollnes T.E., Tonnessen T.I. Clinical experience with microdialysis catheters in pediatric liver transplants. Liver Transpl. 2013, 19:305-314.
142. Sandberg K.L., Brynjarsson H., Hjalmarson O. Transcutaneous blood gas monitoring during neonatal intensive care. Acta Paediatr. 2011, 100:676-679.
143. Kelly A.M., Klim S. Agreement between arterial and transcutaneous PCO2 in patients undergoing non-invasive ventilation. Respir. Med. 2011, 105:226-229.
144. Lima A., van Bommel J., Sikorska K., van Genderen M., Klijn E., Lesaffre E., Ince C., Bakker J. The relation of near-infrared spectroscopy with changes in peripheral circulation in critically ill patients. Crit. Care Med. 2011, 39:1649-1654.